TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01377415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 5 mg/ml infusion 2 ml/h 48 h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 5 mg/ml infusion 2 ml/h 48 h
Study: NCT01129336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
Study: NCT00821132

Intervention type: OTHER
Intervention: Genetic study of ALS families
Description: Collection and analysis of genetic material, medical and family histories from families with ALS
Study: NCT01428674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal Mindful Compassion with Touch
Description: A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal Mindful Compassion with Touch
Description: A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading while extending loving kindness
Description: The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading while extending loving kindness
Description: The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
Study: NCT02589041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraneural sciatic nerve injection
Description: A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Study: NCT03634137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide Group 1
Description: One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide Group 2
Description: One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
Study: NCT04345198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adrenal Artery Ablation
Description: Intervention with adrenal artery ablation is performed in PA patients with resistant hypertension.
Study: NCT00436176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Chronic Care Model
Description: Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
Study: NCT03988010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Sulfate
Description: 200mg/500ml i.v. solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for amantadine sulphate)
Description: 500 cc 0.9% sodium chloride
Study: NCT05799300

Intervention type: PROCEDURE
Intervention: Intrathecal anaesthesia
Description: Low dose 0.5% hyperbaric bupivacaine (1.3mls, 0.65mg) intrathecal anaesthesia.
Study: NCT03019120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1. Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~2. Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~3. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~4. Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~5. At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery.
Study: NCT01933503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 25 mg
Study: NCT01622348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-3100 at 0.16 mg/kg
Description: IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline for Injection
Description: Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMO-3100 at 0.32 mg/kg
Description: IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
Study: NCT02341456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
Study: NCT02484560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell
Study: NCT02456974

Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care

Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.

Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving vancomycin as part of routine clinical care.

Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving teicoplanin as part of routine clinical care.

Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving meropenem as part of routine clinical care.

Intervention type: PROCEDURE
Intervention: blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.

Intervention type: PROCEDURE
Intervention: blood sampling in patients receiving amikacin as part of routine clinical care.
Study: NCT04202744

Intervention type: OTHER
Intervention: Shoulder and core evaluations
Description: Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.

Intervention type: OTHER
Intervention: Shoulder and core evaluations
Description: Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
Study: NCT03312179

Intervention type: DEVICE
Intervention: PCI and DES stenting
Description: Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.

Intervention type: DEVICE
Intervention: PCI and DES stenting
Description: Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.

Intervention type: DEVICE
Intervention: PCI and DES stenting
Description: Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.

Intervention type: DEVICE
Intervention: PCI and DES stenting
Description: Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.

Intervention type: DRUG
Intervention: Incretins
Description: Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
Study: NCT03859687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Description: liquid oral vitamin A supplementation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: No vitamin A supplementation
Description: No vitamin A supplementation
Study: NCT04142060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
Study: NCT03570125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prolon
Description: The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
Study: NCT00722995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
Study: NCT00507741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertafolide
Study: NCT02125032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial low voltage pulsed electromagnetic fields (T-PEMF)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcranial low voltage electromagnetic fields
Study: NCT01674933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duraphat® Fluoride Varnish
Description: 0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
Study: NCT02546063

Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone App
Description: The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
Study: NCT03070184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise capacity VO2 max determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise capacity VO2 max determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized meals
Description: Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized meals
Description: Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate ER
Description: Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate ER
Description: Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
Study: NCT03086915

Intervention type: DRUG
Intervention: Neuromuscular Blocking Agent
Description: Administration of neuromuscular blockers during anesthesia
Study: NCT03410914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Application of hemopatch to the divided end of the pancreas during surgery.
Study: NCT05506865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
Study: NCT00002740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT03514381

Intervention type: DRUG
Group type: OTHER
Intervention: Patients starting a treatment with Doxorubicin and Ifosfamide
Description: 9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)
Study: NCT04264975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
Study: NCT00934700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xenon gas
Description: 30% Xenon gas inhaled for 24 hours
Study: NCT01812798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double Blind Placebo Controlled Food Challenge
Description: All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Double Blind Placebo Controlled Food Challenge
Description: All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour.
Study: NCT01530893

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavanone - supplement
Description: acute single optimal dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanone - food
Description: acute single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanone - placebo
Description: acute single dose (flavanone free)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavone - supplement
Description: acute single optimal dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoflavone - food
Description: acute single optimal dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoflavone - placebo
Description: acute single dose (isoflavone free)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavone - metabolite supplement
Description: acute single optimal dose of commercial product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol - supplement
Description: acute single optimal dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol - food
Description: acute single optimal dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol - placebo
Description: acute single dose (flavan-3-ol free)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin - supplement
Description: acute single optimal dose
Study: NCT05506865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
Study: NCT00179348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Undergo a yoga-based rehabilitation program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Undergo a yoga-based rehabilitation program
Study: NCT02972450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab
Description: The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 MG [Entyvio]
Description: Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 MG [Entyvio]
Description: Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags.
Study: NCT03366961

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conversion surgery
Description: Palliative chemotherapy followed by radical gastrectomy
Study: NCT01630954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction and evacuation
Description: In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction and evacuation
Description: In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
Study: NCT02046278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSeal™ Kit
Study: NCT01892904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE20/DRSP(BAY86-5300)
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP(BAY86-5300)
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
Study: NCT02159885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring